Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10048912 | 0.90 | CNR2 (0.69) | CNR2CNR1KCNH2 | |
| SCHEMBL10048960 | 0.90 | CNR2 (0.62) | CNR2CNR1P2RX3KCNH2 | |
| SCHEMBL13605778 | 0.88 | CNR2 (0.48) | CNR2CNR1P2RX3KCNH2 | |
| SCHEMBL13605687 | 0.88 | CNR2 (0.49) | CNR2CNR1P2RX3KCNH2 | |
| SCHEMBL10048934 | 0.87 | CNR2 (0.58) | CNR2CNR1P2RX3KCNH2 | |
| SCHEMBL10048963 | 0.87 | CNR2 (0.59) | CNR2CNR1KCNH2 | |
| SCHEMBL13605679 | 0.87 | CNR2 (0.53) | CNR2CNR1P2RX3KCNH2 | |
| SCHEMBL13605683 | 0.86 | CNR2 (0.46) | CNR2CNR1P2RX3KCNH2 | |
| SCHEMBL10048851 | 0.85 | CNR2 (0.45) | CNR2CNR1P2RX3KCNH2 | |
| SCHEMBL13605697 | 0.85 | CNR2 (0.55) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284303-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-15 | — | — | US | disclosed |
| EP-2142531-B1 | BENZIMIDAZOLE CANNABINOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-08 | — | — | EP | disclosed |
| US-8524757-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-03 | — | — | US | disclosed |
| US-8524757-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-03 | — | — | US | disclosed |
| US-8193369-B2 | Benzimidazole cannabinoid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-8193369-B2 | Benzimidazole cannabinoid agonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-05 | — | — | US | disclosed |
| US-20100041702-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041702-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-18 | — | — | US | disclosed |
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | US | disclosed |
| WO-2008119694-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885P2RX3 194/4885 |
| US-20100041702-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885P2RX3 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.